苏格兰成人哮喘患者COVID-19严重结局风险:全国性事件队列研究
该全国性事件队列研究基于苏格兰EAVE II链接数据集,纳入2020年3月1日至2021年7月27日所有≥18岁成人,评估哮喘与COVID-19住院及ICU入住或死亡风险的关系。结论建议近2年需≥2个疗程口服糖皮质激素或曾有哮喘住院者优先接种加强疫苗。
要点
- 近2年≥2个疗程口服糖皮质激素或曾因哮喘住院者应优先接种加强疫苗。
核心结论
- 成人哮喘患者COVID-19住院及ICU入住或死亡风险升高,且风险随近期口服糖皮质激素疗程数增加而增加。
- 近2年需≥2个疗程口服糖皮质激素或2020年3月1日前曾因哮喘住院者应视为加强疫苗接种优先人群。
研究设计与样本
- 全国性事件队列研究,基于苏格兰EAVE II链接数据集,纳入2020年3月1日至2021年7月27日所有≥18岁成人。
- 使用Cox比例风险模型计算调整后风险比(aHR)及95%CI,按近2年口服糖皮质激素处方或既往哮喘住院分层。
- 分析调整了年龄、性别、社会经济状态、合并症、既往住院和疫苗接种状态。
临床怎么用
- 呼吸科医生应识别近2年需≥2个疗程口服糖皮质激素或曾因哮喘住院的成人哮喘患者。
- 将上述患者视为COVID-19加强疫苗接种的优先人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is considerable uncertainty over whether adults with asthma should be offered booster vaccines against SARS-CoV-2 and, if so, who should be prioritised for booster vaccination. We were asked by the UK's Joint Commission on Vaccination and Immunisation to undertake an urgent analysis to identify which adults with asthma were at an increased risk of serious COVID-19 outcomes to inform deliberations on booster COVID-19 vaccines. METHODS: This national incident cohort study was done in all adults in Scotland aged 18 years and older who were included in the linked dataset of Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II). We used data from EAVE II to investigate the risk of COVID-19 hospitalisation and the composite outcome of intensive care unit (ICU) admission or death from COVID-19 among adults with asthma. A Cox proportional hazard model was used to derive adjusted hazard ratios (HRs) and 95% CIs for the association between asthma and COVID-19 hospital admission and ICU admission or death, stratified by markers of history of an asthma attack defined by either oral corticosteroid prescription (prednisolone, prednisone, and dexamethasone) in the 2 years before March 1, 2020, or hospitalisation for asthma before March 1, 2020. Analyses were adjusted for age, sex, socioeconomic status, comorbidity, previous hospitalisation, and vaccine status. FINDINGS: Between March 1, 2020, and July 27, 2021, 561 279 (12·7%) of 4 421 663 adults in Scotland had clinician-diagnosed-and-recorded-asthma. Among adults with asthma, 39 253 (7·0%) had confirmed SARS-CoV-2 infections, of whom 4828 (12·3%) were admitted to hospital for COVID-19 (among them, an estimated 600 [12·4%] might have been due to nosocomial infections). Adults with asthma were found to be at an increased risk of COVID-19 hospital admission (adjusted HR 1·27, 95% CI 1·23-1·32) compared with those without asthma. When using oral corticosteroid prescribing in the preceding 2 years as a marker for history of an asthma attack, the adjusted HR was 1·54 (95% CI 1·46-1·61) for those with three or more prescribed courses of oral corticosteroids, 1·37 (1·26-1·48) for those with two prescribed courses, 1·30 (1·23-1·37) for those with one prescribed course, and 1·15 (1·11-1·21) for those without any courses, compared with those aged 18 years or older without asthma. Adults with asthma were found to be at an increased risk of COVID-19 ICU admission or death compared with those without asthma (adjusted HR 1·13, 95 % CI 1·05-1·22). The adjusted HR was 1·44 (95% CI 1·31-1·58) for those with three or more prescribed courses of oral corticosteroids, 1·27 (1·09-1·48) for those with two prescribed courses, 1·04 (0·93-1·16) for those with one prescribed course, and 1·06 (0·97-1·17) for those without any course, compared with adults without asthma. INTERPRETATION: Adults with asthma who have required two or more courses of oral corticosteroids in the previous 2 years or a hospital admission for asthma before March 1, 2020, are at increased risk of both COVID-19 hospitalisation and ICU admission or death. Patients with a recent asthma attack should be considered a priority group for booster COVID-19 vaccines. FUNDING: UK Research and Innovation (Medical Research Council), Research and Innovation Industrial Strategy Challenge Fund, Health Data Research UK, and Scottish Government.
引用
- Shi T, Pan J, Vasileiou E, et al. Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study. Lancet Respir Med. 2022. PMID: 35033224. doi:10.1016/S2213-2600(21)00543-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。